Announce data updates from ongoing RP1 skin cancer cohorts
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 Feb 2023
- Due
- 30 Sep 2023
- Delivered
- by 7 Nov 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“updates from ongoing RP1 skin cancer cohorts including anti-PD1 failed non-melanoma skin cancer (CSCC predominant) and the RP1 monotherapy clinical trial in organ transplant recipients with skin cancer... expected to be announced in Q3 2023”
What we found
Evidence strength A What the grades mean
The company announced data updates for both cohorts in November and December 2023, which occurred after the Q3 2023 deadline.
-
A Replimune Group, Inc. 8-K filed 2023-11-07
“A recap of interim data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant recipients with skin cancer recently presented at SITC 2023” ✓ confirmed on the page
-
A Replimune Group, Inc. 8-K filed 2023-11-07
“The Company plans to provide a data update of the first 30 patients with at least 6 months follow up on its conference call in early December.” ✓ confirmed on the page
Market reaction: the shares moved -10.4% against the S&P 500 over the three sessions around the disclosure (6 Nov 2023 to 9 Nov 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Announce
- Deliverable
- RP1 skin cancer cohorts data updates
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-REPL-002701 · Corrections policy